Rejuvenate Bio

What it is

Rejuvenate Bio was co-founded by George Church and Noah Davidsohn at Harvard. Its core thesis: combinatorial gene therapies delivered via AAV can deliver longevity-relevant phenotypes in mammals.

Approach

• Combinations of longevity-associated genes (e.g. FGF21, TGF-β1, α-klotho variants) delivered as gene therapies.
• Initial commercial focus on companion dogs with age-related disease (heart disease, kidney disease).
• Translational pipeline aimed at human indications.

Reported results

Pre-clinical mouse studies have reported reversal of age-related phenotypes from a 3-gene combination AAV; replication and durability data continue to develop.

Why this matters

• Gene therapy can deliver sustained protein-expression changes that are difficult to achieve with small molecules.
• Combinatorial approaches recognise the multi-pathway nature of aging.
• The dog-first commercialisation parallels Loyal’s strategy.

Open questions

• Safety profile in long-lived mammals.
• Durability of expression.
• Tissue specificity.
• Translational efficiency from mouse to dog to human.

Related entries

Klotho, Loyal, Cardiovascular disease.